Clinical Validation of the M5L Lung CAD

Status Completed

Clinical Trial Summary

To compare the diagnostic performance and time efficiency of Computer-Aided Detection (CAD) assisted reading for the identification of pulmonary nodules in chest Computed Tomography (CT) from oncological patients with that of unassisted reading.

Clinical Trial Description

The main aim of this study is to compare the diagnostic performance of CAD assisted interpretation with that of unassisted reading in the detection of lung metastases in consecutive patients staged for extrathoracic malignancies. This study also aims at validating a new Web/Cloud based workflow for the use of CAD systems in clinical practice, not requiring installation of additional software or hardware and potentially representing a cost-effective CAD solution for clinical facilities. ;

Study Design

Related Conditions & MeSH terms

Lung Cancer Metastatic

Clinical Trial Details

NCT number	NCT03179150
Study type	Observational
Source	Candiolo Cancer Institute - IRCCS
Contact
Status	Completed
Phase	N/A
Start date	September 1, 2015
Completion date	June 1, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05452005` - Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT03693339` - Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation	Phase 2
Completed	`NCT03970564` - Neck Ultrasound by Respiratory Physicians in Patients With Lung Cancer
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Terminated	`NCT02308865` - Early Palliative Care in Metastatic Lung Cancer in Northern France	N/A
Not yet recruiting	`NCT03703596` - Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC	Phase 2
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Recruiting	`NCT05537922` - I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Active, not recruiting	`NCT04986670` - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer	N/A
Completed	`NCT03755102` - A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Early Phase 1
Not yet recruiting	`NCT03638765` - Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer	Phase 1
Recruiting	`NCT02976740` - SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy	Phase 2
Recruiting	`NCT04085315` - Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	Phase 1
Recruiting	`NCT03693326` - PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities	Phase 2
Recruiting	`NCT05860296` - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT04964960` - Pembro+Chemo in Brain Mets	Phase 2
Completed	`NCT04973436` - DBT for Metastatic Lung Cancer	N/A
Recruiting	`NCT05078047` - Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO	Phase 3
Active, not recruiting	`NCT03057106` - Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC	Phase 2
Recruiting	`NCT05144529` - A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC	Phase 2